EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 269 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant MOST POPULAR Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds October 2, 2021 En gran cantidad de casos el exito o examen experto os... August 21, 2023 Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... July 23, 2020 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... June 7, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... Co-Existing with COVID-19: Should I go back to work? Do I... Primary Tumour Resection Does Not Prolong OS in Patients with Treatment-Naïve... ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December
